Baird Medical Expands U.S. Presence in Interventional Thyroid Care

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) is making significant strides in the United States with its innovative Microwave Ablation (MWA) technology for treating benign thyroid conditions. On February 25, 2026, the company announced advancements in clinical applications that align with its goal of enhancing global growth and improving patient access to minimally invasive therapies.

The progress is evident in the work of Samer Nakhle, M.D., FACE, ECNU, who serves as the Medical Director of Palm Medical Group in Las Vegas, Nevada. Dr. Nakhle has effectively utilized Baird Medical’s technology in benign thyroid applications, which is expected to lead to broader adoption of these cutting-edge treatments across various medical environments.

In addition to Dr. Nakhle’s contributions, Sophie Dream, M.D., MPH, FACS, an Associate Professor and Chief of the Section of Endocrine Surgery at the University of Alabama at Birmingham, is playing a pivotal role in advancing this national initiative. Dr. Dream has implemented Baird Medical’s platforms to address benign thyroid conditions, thereby encouraging the wider medical community to embrace these effective, tissue-sparing interventions.

Mark Saxton, the U.S. CEO of Baird Medical, emphasized the importance of integrating their systems into both academic and private practices. He stated, “Integrating our systems into leading academic and private practices drives our core mission. These recent milestones validate our commercial roadmap and ensure more physicians have the tools necessary to elevate patient care.”

Baird Medical is recognized as a leader in the field of minimally invasive diagnostics and treatment. The company is dedicated to research and development, focusing on surgical robotic systems and innovative surgical instruments aimed at improving patient outcomes. This commitment extends to fostering strategic collaborations with top academic institutions, enhancing not only surgical assistance but also proactive diagnostic and preventive healthcare strategies.

As an FDA 510(k)-certified medical device company, Baird Medical’s solutions have been implemented in over 30 prestigious hospitals and clinics across the United States, including renowned institutions such as Mayo Clinic, Tulane Medical Center, and Columbia University Medical Center. In addition, the company holds a dominant market position in China for thyroid microwave ablation devices and consumables, with its minimally invasive treatment products gradually expanding their reach into more than 20 countries worldwide.

The company’s recent advancements signal a strong commitment to enhancing patient care through innovative technologies. While Baird Medical is optimistic about its growth trajectory, it acknowledges inherent risks associated with expanding its business, particularly in the competitive healthcare landscape.

Readers should be aware that the information provided includes forward-looking statements, which involve risks and uncertainties that could lead to actual results differing materially from those anticipated. Baird Medical does not undertake any obligation to update these statements as conditions change.

For more information, contact Eric Huang, PR Liaison at Baird Medical Investment Holdings Ltd., via phone at +1 (888) 508-6228 or email at [email protected].